Page last updated: 2024-11-04

oxyphenonium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxyphenonium: A quaternary ammonium anticholinergic agent with peripheral side effects similar to those of ATROPINE. It is used as an adjunct in the treatment of gastric and duodenal ulcer, and to relieve visceral spasms. The drug has also been used in the form of eye drops for mydriatic effect. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5749
CHEMBL ID1201286
CHEBI ID94329
SCHEMBL ID250614
MeSH IDM0015691

Synonyms (38)

Synonym
methocidin
metocidina [inn-spanish]
methocidinum [inn-latin]
methocidine [inn-french]
hydroxymethylgramicidin
oxyphenonium
oxyphenonium cation
oxyphenonium ion
DB00219
oxiphenonum
ethanaminium, 2-((cyclohexylhydroxyphenylacetyl)oxy)-n,n-diethyl-n-methyl-
AKOS000510119
L000855
14214-84-7
2-(2-cyclohexyl-2-hydroxy-2-phenylacetyl)oxyethyl-diethyl-methylazanium
NCGC00018256-04
NCGC00018256-05
CHEMBL1201286
unii-d2g5508y7i
d2g5508y7i ,
1407-05-2
methocidin [dcf:inn]
gtpl7257
{2-[(2-cyclohexyl-2-hydroxy-2-phenylacetyl)oxy]ethyl}diethylmethylazanium
oxyphenonium [who-dd]
ethanaminium, 2-((2-cyclohexyl-2-hydroxy-2-phenylacetyl)oxy)-n,n-diethyl-n-methyl-
2-(2-cyclohexyl(hydroxy)phenylacetoxy)-n,n-diethyl-n-methylethanaminium
oxyphenonium [vandf]
AKOS022121993
SCHEMBL250614
2-{[cyclohexyl(hydroxy)phenylacetyl]oxy}-n,n-diethyl-n-methylethanaminium
STL325089
DTXSID8048571
AB00383041_13
2-(2-cyclohexyl-2-hydroxy-1-oxo-2-phenylethoxy)ethyl-diethyl-methylammonium
CHEBI:94329
SBI-0207023.P001
BRD-A14208071-004-10-7

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Oxyphenonium-treated retinas showed no damage."( Variable effects of previously untested muscarinic receptor antagonists on experimental myopia.
Luft, WA; Ming, Y; Stell, WK, 2003
)
1.04

Toxicity

ExcerptReferenceRelevance
" In conclusion, the pharmacological profile of the aforementioned combination in the dosages employed in mice, rats, guinea-pigs, rabbits and dogs shows that it is safe and well tolerated."( Safety pharmacology of a combination of tinidazole and oxyphenonium bromide.
Bhatt, A; David, J; Joseph, T; Nagarani, A; Vaidya, A; Venkataraman, V, 1997
)
0.54
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

ExcerptReferenceRelevance
" A quantitative description of liver function in terms of regional distribution and elimination rate constants will require either a pharmacokinetic model that expressly includes the effects of bilirubin, the development of new anionic hepatobiliary agents capable of displacing endogenous bilirubin from transport binding sites, or the development of new hepatobiliary agents that use a different clearance mechanism from that used by bilirubin."( Hepatic clearance mechanism of Tc-99m-HIDA and its effect on quantitation of hepatobiliary function: Concise communication.
Cooper, M; Faith, W; Harvey, E; Loberg, M; Ryan, J; Sikorski, S, 1979
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
acylcholineA choline ester formed from choline and a carboxylic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID625294Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID771314Cellular uptake in human HEK293 cells assessed as human OCT2-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis relative to passive uptake2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID771315Cellular uptake in human HEK293 cells assessed as human OCT1-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis relative to passive uptake2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID771317Cellular uptake in human HEK293 cells assessed as human OCT1-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID771316Cellular uptake in human HEK293 cells assessed as human OCT2-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (164)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990126 (76.83)18.7374
1990's16 (9.76)18.2507
2000's13 (7.93)29.6817
2010's9 (5.49)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.71 (24.57)
Research Supply Index5.29 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index60.89 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (5.91%)5.53%
Reviews2 (1.08%)6.00%
Case Studies2 (1.08%)4.05%
Observational0 (0.00%)0.25%
Other171 (91.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]